Last 35 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -10.44 | — | 24.09 | 92.23 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 6.90 | 5.84 | 38.51 | 10.37 | 10.16 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 57.46 | 8.51 | 78.14 | 18.79 | 16.28 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | 83.80 | 56.05 | 1991.53 | 40.62 | 312.38 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 76.59 | 200.27 | 187.85 | 57.74 | 72.49 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 114.98 | — | 134.00 | 57.25 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Caris Life Sciences, Inc.'s operating margin was 2.4% in Q1 2026, down 15.5 pp QoQ and up 50.4 pp YoY. The trailing four-quarter average of 11.3% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 66.4% | — | 75.4% | 68.0% | 62.7% | 47.2% | 53.6% | 50.0% | 47.8% | 63.4% | 61.5% | 61.9% | 48.7% |
| — | — | +40.6% | +36.0% | +31.2% | -25.6% | -12.8% | -19.2% | -2.0% | +33.4% | +27.8% | +28.6% | -1.2% | |
| Operating Margin | 5.6% | 2.4% | 17.9% | 15.1% | 9.9% | -47.9% | 65.9% | 59.3% | 60.4% | 56.1% | 45.0% | 43.6% | 32.0% |
| — | +105.1% | -72.8% | -74.6% | -83.6% | -185.5% | +46.5% | +36.1% | +88.7% | +99.8% | +40.6% | +33.7% | +0.7% | |
| Net Margin | -66.2% | -0.2% | 28.0% | 11.2% | -39.6% | -84.8% | 50.7% | 44.3% | 44.2% | 22.1% | 19.5% | -0.8% | -1.3% |
| — | +99.7% | -44.8% | -74.7% | -189.5% | -483.0% | +159.7% | +5455.8% | +3592.8% | +182.7% | +542.7% | -109.3% | -107.6% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -93.2% | -0.1% | 15.5% | 5.2% | -15.9% | — | 6.6% | 5.1% | 5.0% | 2.0% | 2.2% | -0.1% | -0.2% |
| — | — | +136.3% | +2.1% | -416.8% | — | +195.0% | +5731.4% | +2702.2% | +78.6% | +423.4% | -106.8% | -107.3% | |
| ROA | -73.2% | -0.0% | 7.8% | 2.5% | -11.5% | -5.8% | 1.6% | 1.3% | 1.4% | 0.5% | 0.5% | -0.0% | -0.0% |
| — | +99.2% | +372.4% | +86.2% | -952.2% | -1249.8% | +209.6% | +6142.2% | +3037.8% | +87.0% | +432.1% | -107.1% | -107.3% | |
| ROIC | 21.3% | — | 25.3% | 16.1% | — | -10.8% | 1.8% | 1.5% | 1.5% | 1.0% | 1.0% | 0.9% | 0.9% |
| — | — | +1312.1% | +962.7% | — | -1153.7% | +84.5% | +61.9% | +61.0% | +34.4% | +4.4% | -0.3% | -2.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Caris Life Sciences, Inc.'s Debt/EBITDA ratio is 0.0x, down from 6.4x last quarter — comfortably within a safe range. The current ratio has improved 569.1% YoY to 7.05x, strengthening the short-term liquidity position. Debt/Equity has declined for 4 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.66 | 0.00 | 0.66 | 0.89 | 0.93 | — | 2.82 | 2.41 | 2.52 | 2.49 | 3.16 | 2.88 | 3.05 |
| — | — | -76.7% | -63.0% | -63.2% | — | -10.7% | -16.3% | -17.5% | -17.9% | +1.8% | -6.8% | +3.1% | |
| Debt / EBITDA | 5.60 | 0.03 | 6.37 | 11.38 | 17.17 | — | 22.75 | 22.70 | 23.56 | 29.19 | 33.37 | 32.14 | 34.34 |
| — | — | -72.0% | -49.9% | -27.1% | — | -31.8% | -29.4% | -31.4% | -23.7% | -0.3% | -9.6% | +11.3% | |
| Current Ratio | 7.85 | 7.05 | 7.85 | 9.93 | 9.24 | 1.05 | 0.72 | 0.45 | 0.74 | 0.67 | 0.82 | 0.75 | 1.07 |
| — | +569.1% | +995.0% | +2098.8% | +1142.9% | +57.2% | -12.6% | -39.6% | -30.3% | -61.4% | -33.2% | -43.0% | +96.8% | |
| Quick Ratio | 7.85 | 7.05 | 7.85 | 9.36 | 8.79 | 0.83 | 0.72 | 0.45 | 0.74 | 0.67 | 0.82 | 0.75 | 1.07 |
| — | +750.7% | +995.0% | +1971.9% | +1082.4% | +23.6% | -12.6% | -39.6% | -30.3% | -61.4% | -33.2% | -43.0% | +96.8% | |
| Interest Coverage | -0.20 | 0.41 | 58.47 | 2.80 | -2.74 | -7.03 | — | 4.58 | 4.33 | 8.27 | 2.10 | 1.97 | 0.77 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 35 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying CAI stock.
Caris Life Sciences, Inc.'s current P/E is -10.4x. The average P/E over the last 2 quarters is 58.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Caris Life Sciences, Inc.'s current operating margin is 5.6%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Caris Life Sciences, Inc.'s business trajectory between earnings reports.